Condition: Gastroesophageal-junction Cancer · Monoclonal Antibody · Gastric Cancer · Sponsor: Shanghai Henlius Biotech
This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced/metastatic adenocarcinoma of the gastric and/or gastroesophageal junction (G/GEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio. Enrolled subjects shall be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first).
This description comes directly from the study's public registry record.
Ying Li · +86 18810366427 · ying_li1@henlius.com
Always discuss trial participation with your own doctor first.
| Los Angeles Cancer Network | Anaheim, California, United States | Recruiting |
| OPN - Oncology Physician Network (Los Alamitos) | Los Alamitos, California, United States | Recruiting |
| Banner MD Anderson Cancer Center | Greeley, Colorado, United States | Recruiting |
| Advanced Research LLC | Deerfield Beach, Florida, United States | Recruiting |
| Florida Cancer Specialist - South | Fort Myers, Florida, United States | Recruiting |
| BRCR Medical Center | Plantation, Florida, United States | Recruiting |
| Napa Research | Pompano Beach, Florida, United States | Recruiting |
| Florida Cancer Specialist - North | St. Petersburg, Florida, United States | Recruiting |
| Florida Cancer Specialist - East | West Palm Beach, Florida, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Mission Cancer + Blood (Exigent Network) | Des Moines, Iowa, United States | Recruiting |
+ 196 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06532006